text.skipToContent text.skipToNavigation
Pharma & Biotech

Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 1 Million

Catalog #: 4Y-101C
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 1 million cells
Size
Compare
EA

Product Overview

Mobilized peripheral blood CD34+ hematopoietic stem and progenitor cells are positively selected using a immunomagnetic CD34 microbead labeling system. Cells are cryopreserved in Lonza Cryo Media in a cryovial. Cell purity is determined post thaw using a FACS assay. Count and viability is determined using AO/PI. Cells are collected from healthy donors following IRB protocols

Manufactured by AllCells®

Benefits

  • Obtain large quantities of CD34+ from a donor
  • Certificate of analysis (CoA) provided for each lot purchased
  • Test negative for mycoplasma, bacteria, yeast, and fungi
  • HIV-1, Hepatitis B and Hepatitis C are not detected for all donors and/or cell lots

Applications

  • CAR-T therapy development
  • iPSC generation
  • Autoimmune disease
  • Immunology
  • Cancer research

Content & Storage

Content

1 x Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood containing ≥ 1 million cells

Instructions

Safety Data Sheets (SDS)

Certificate of Analysis (CoA)

Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.

Need a Quote or Any Support?

Request a local representative to get back to you with additional information or pricing.

Immunotherapy and Hematopoietic Knowledge Center

The Immunotherapy and Hematopoietic Knowledge Center is dedicated to sharing interesting articles and resources related to immuno and hematopoietic research.

Subscribe to our eNewsletter

Keep up to speed on the latest scientific developments, events, tips and tools from Lonza.

We use cookies to deliver the best service to you. By continuing to browse the site, you are agreeing to our use of cookies.Ok